CVS Pharmacy, Inc. Naproxen Sodium Capsules, 220 mg (NSAID) Drug Facts | naproxen sodium
Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)*
*nonsteroidal anti-inflammatory drug
Pain reliever/fever reducer
Allergy alert: Naproxen sodium may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:
If an allergic reaction occurs, stop use and seek medical help right away.
Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you:
ask a health professional before use. It is especially important not to use naproxen sodium during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
|
|
|
|
|
|
FD&C Blue #1, gelatin, glycerin, lactic acid, mannitol, pharmaceutical ink, polyethylene glycol, povidone, propylene glycol, purified water, sorbitan, sorbitol
1-800-719-9260
See New Warnings Information
Naproxen Sodium Capsules, 220 mg (NSAID)
Pain Reliever/Fever Reducer
†Liquid Filled Capsules
Not Actual Size, See Side Panel (Used on packaging configurations containing an image of a broken capsule graphic only)
Manufacturer
CVS Pharmacy
Active Ingredients
Source
- U.S. National Library of Medicine
- DailyMed
- Last Updated: 4 May 2013
Drugs and Medications
Naproxen [Roxane Laboratories, Inc]
NAPROXEN Oral Suspension USP, 125 mg per 5 mL
Naproxen sodium [Hikma Pharmaceutical]
Naproxen Sodium Tablets, USPRx Only 09/09
Naproxen tablets [Dr. Reddy's Laboratories Limited]
Naproxen Tablets
NAPROXEN SODIUM TABLETS, USP
Naproxen [PD-Rx Pharmaceuticals, Inc.]
Naproxen Tablets, USP
Clinical Trials
Naproxen Sodium ER Pharmacokinetic Study
To determine the pharmacokinetic profile of the investigational product following dosing under fed conditions.
The purpose of this study is to assess the bioequivalence of Naproxen sodium 220 mg + Pseudoephedrine Hydrochloride 120 mg Extended Release tablets of with Aleve Cold and Sinus in healthy...
Fast & Fed Pharmacokinetic (PK) Study
The purpose of this study is to provide information on how well an extended release formulation (a medication that is released and absorbed over a longer period of time than a regular rele...
Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan
To compare the pharmacokinetic profile of the proposed extended- release tablet of naproxen sodium 660 mg relative to two tablets of Naprelan 500 mg following single dose administration fo...
The purpose of this study is to assess the bioequivalence of Naproxen sodium 220 mg + Pseudoephedrine Hydrochloride 120 mg Extended Release tablets of with Aleve Cold and Sinus in healthy...
PubMed Articles
Reduced Ulcerogenic Potential and Antiarthritic Effect of Chitosan-Naproxen Sodium Complexes.
The purpose of this research was to address the utility of naproxen sodium-chitosan spray-dried complexes for antiulcer and antiarthritic activities. The cold stress technique was used to examine the...
PURPOSE: To understand the transformation pathways amongst anhydrate/hydrate solid forms of sodium naproxen and to highlight the importance of a polymorphic dihydrate within this context. METHODS: Mul...
Evaluation of the use of sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea.
Evaluation of: Cady RK, Diamond ML, Diamond MP et al. Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache 51(5...
To investigate whether low-dose naproxen sodium (220 mg twice a day) interferes with aspirin's antiplatelet effect in healthy subjects.
Naproxen Interferes with the Assembly of Aβ Oligomers Implicated in Alzheimer's Disease.
Experimental and epidemiological studies have shown that the nonsteroidal antiinflammatory drug naproxen may be useful in the treatment of Alzheimer's disease. To investigate the interactions of napro...
